Zero HIV transmissions in PARTNER 2 study after gay couples had sex 77,000 times without condoms – an undetectable viral load stops HIV
3 August 2018. Related: Conference reports, HIV prevention and transmission.
Conference reports
DTG/3TC dual therapy is non-inferior to triple-ART in GEMINI study
3 August 2018. Related: Conference reports, Antiretrovirals.
Once-daily reduced dose darunavir/ritonavir (400 mg/100 mg) is non-inferior to twice-daily lopinavir/ritonavir in South African switch study
3 August 2018. Related: Conference reports, Treatment strategies.
Superior efficacy with dolutegravir-based ART compared with other regimens at 6 months: real-world data from Brazil
3 August 2018. Related: Conference reports, Antiretrovirals, Treatment access.
WHO recommends dolutegravir widely but women’s access will depend on contraception provision (2018)
3 August 2018. Related: Conference reports, Women's health, Pregnancy, Guidelines.
No additional neural tube defects among a further 170 preconception dolutegravir exposures in Botswana: Tsepamo study (July 2018)
3 August 2018. Related: Conference reports, Pregnancy.
Swifter viral load suppression with dolutegravir vs efavirenz in late pregnancy: results from DolPHIN-1
3 August 2018. Related: Conference reports, Pregnancy.
First randomised kick-and-kill cure study fails to reduce HIV reservoir: RIVER study reports vorinostat and vaccines show activity, but not enough
3 August 2018. Related: Conference reports, Cure-related research.
Using PrEP with feminising hormone therapy supports daily PrEP dosing for transwomen
3 August 2018. Related: Conference reports, PK and drug interactions, HIV prevention and transmission.
Daily and on-demand PrEP both prevent HIV in Prévenir study: high adherence by gay Parisians
3 August 2018. Related: Conference reports, HIV prevention and transmission.
AIDS 2018 online: links to selected webcasts
3 August 2018. Related: Conference reports.
10th International Workshop on HIV Paediatrics – first reports
3 August 2018. Related: Conference reports, Paediatric care.
Preconception safety signal with dolutegravir: data from the Tsepamo study
3 August 2018. Related: Conference reports, Pregnancy.
What to watch: HIV cure-related research at AIDS 2018
20 July 2018. Related: Conference reports, Cure-related research.
AIDS 2018: Programme online and late-breaker highlights announced three weeks before the conference
11 July 2018. Related: Conference reports.
19th International Workshop on Clinical Pharmacology, 22–24 May 2018, Baltimore
29 June 2018. Related: Conference reports.
Unbound dolutegravir plasma concentrations unchanged in pregnancy and standard dosing crosses the placenta in placental perfusion model
29 June 2018. Related: Conference reports, Pregnancy, PK and drug interactions.
Etravirine dispersible paediatric tablet has greater bioavailability when dispersed in water compared to swallowed whole
29 June 2018. Related: Conference reports, Paediatric care, PK and drug interactions.
Reduced exposure to elvitegravir in pregnancy: results from the PANNA Network
29 June 2018. Related: Conference reports, Pregnancy, PK and drug interactions.
Rifabutin dosed 2.5 mg/kg daily with lopinavir/r in children achieves comparable exposure to adults
29 June 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
No clinically relevant reduction in oral cabotegravir when co-administered with rifabutin
29 June 2018. Related: Conference reports, PK and drug interactions.
Boosted darunavir 800/100 mg twice daily might overcome interaction with rifampicin
29 June 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Efavirenz side effects and other drug-drug interactions are common in Ugandan cohort
29 June 2018. Related: Conference reports, PK and drug interactions, Side effects.
19th International Workshop on Clinical Pharmacology, 22–24 May 2018, Baltimore
8 June 2018. Related: Conference reports.
Dolutegravir 50 mg twice daily sufficient with rifampicin but levels reduced significantly with 100 mg once daily
8 June 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Vaginal ring reduces efavirenz but not atazanavir exposures
8 June 2018. Related: Conference reports, PK and drug interactions.
Dispersible paediatric versions of dolutegravir provide higher bioavailability than immediate release formulations
8 June 2018. Related: Conference reports, Paediatric care.
Fourth Joint Conference of BHIVA/BASHH (4th BHIVA/BASHH)
21 May 2018. Related: Conference reports.
Low PEP and PrEP awareness among trans people in London and their partners
21 May 2018. Related: Conference reports, HIV prevention and transmission.
Low awareness of PrEP in BME communities in Leeds but high interest in use
21 May 2018. Related: Conference reports, HIV prevention and transmission.
Younger people living with HIV more likely to have a positive self image
21 May 2018. Related: Conference reports, Other news.
Zero or negligible risks of HIV, HBV or HCV transmission by biting or spitting
21 May 2018. Related: Conference reports, HIV prevention and transmission.
UK-CAB community representation on guideline panels and research studies
21 May 2018. Related: Conference reports, Treatment advocacy.
Fourth Joint Conference of BHIVA/BASHH (4th BHIVA/BASHH)
1 May 2018. Related: Conference reports.
Almost 1 in 8 people with symptoms turned away from sexual health clinics in SE London: 40% are under 25 and 6% under 18 years old
1 May 2018. Related: Conference reports, Treatment access, Women's health, Pregnancy, HIV prevention and transmission.
A new framework for best HIV care: BHIVA Standards of Care revised and updated (2018)
1 May 2018. Related: Conference reports, Guidelines.
Key changes to upcoming UK HIV pregnancy guidelines (2018)
1 May 2018. Related: Conference reports, Pregnancy, Guidelines.
Pregnancy studies at 4th Joint BHIVA/BASHH Conference
1 May 2018. Related: Conference reports, Pregnancy.
Meta-analysis of TAF vs TDF in boosted vs unboosted regimens
1 May 2018. Related: Conference reports, Antiretrovirals.
Meta-analysis of dolutegravir in naive, experienced and switch studies
1 May 2018. Related: Conference reports, Antiretrovirals.
Not claptrap: kissing as the strongest route for oral gonorrhoea
1 May 2018. Related: Conference reports, Coinfections and complications.
Rapid PrEP uptake in Scotland exceeds expectations
1 May 2018. Related: Conference reports, HIV prevention and transmission.
Drug cost savings from routine use of generic ARVs: safety and efficacy in practice
1 May 2018. Related: Conference reports, Antiretrovirals, Treatment access.
CROI 2018: third reports
16 April 2018. Related: Conference reports.
No increased risk of IRIS in people with low CD4 counts receiving raltegravir in the REALITY trial
16 April 2018. Related: Conference reports, Coinfections and complications.
Isoniazid preventive TB therapy in pregnancy and postpartum: recommendations now need to be re-evaluated
16 April 2018. Related: Conference reports, Women's health, Pregnancy, TB coinfection.
Efavirenz might decrease effectiveness of the vaginal contraceptive ring
16 April 2018. Related: Conference reports, Pregnancy, PK and drug interactions.
Switch to TAF appears safe and effective in adolescents: similar PK to adults
16 April 2018. Related: Conference reports, Paediatric care.
Doubling raltegravir dose could overcome interaction with rifampicin in children aged 2 to 6
16 April 2018. Related: Conference reports, Paediatric care, PK and drug interactions, TB coinfection.
Twice-daily bictegravir does not overcome drug interaction with rifampicin
16 April 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Reducing risk of myocardial infarction (MI) in HIV positive people
16 April 2018. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications, Coinfections and complications.
M184V mutation associated with increased risk of viral blip but not viral failure with 3TC-based dual therapy
16 April 2018. Related: Conference reports, Treatment strategies, Drug resistance.
CROI 2018: second reports
30 March 2018. Related: Conference reports.
Ibalizumab 24-week phase 3 results and susceptibility to drug-resistant HIV
30 March 2018. Related: Conference reports, Antiretrovirals.
Statin use might reduce risk of cancer in HIV positive people
30 March 2018. Related: Conference reports, Cancer and HIV.
Rate of bone loss on ART slows after the first year
30 March 2018. Related: Conference reports, Side effects.
Standard dose of dolutegravir sufficient in late pregnancy: interim results from DolPHIN-1 study
30 March 2018. Related: Conference reports, Pregnancy.
Women’s risk of becoming HIV positive increases three-fold in late pregnancy and four-fold postpartum
30 March 2018. Related: Conference reports.
Cure research at CROI 2018: defining and reducing the reservoir and the risks from interrupting treatment
30 March 2018. Related: Conference reports, Cure-related research.
25th Conference on Retroviruses and Opportunistic Infections (CROI 2018)
14 March 2018. Related: Conference reports.
Inching towards an HIV cure: bNAb and TLR-7 agonist reduce viral rebound off-ART in macaques
14 March 2018. Related: Conference reports, Cure-related research.
No HIV evolution in plasma or lymph nodes on suppressive ART and no impact from further intensification
14 March 2018. Related: Conference reports, Cure-related research.
Dual therapy can reduce TB prophylaxis from nine months to one: fewer side effects and more people complete treatment
14 March 2018. Related: Conference reports, TB coinfection.
Twice-daily dolutegravir is effective and tolerable with rifampicin
14 March 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Once-daily tenofovir alafenamide appears sufficient when dosed with rifampicin
14 March 2018. Related: Conference reports, TB coinfection.